苏州诺洁贝生物技术

Nuojiebei Biotech is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of innovative gene therapies. Founded in 2020, the company focuses on utilizing Adeno-Associated Virus (AAV) vectors to treat genetic disorders, particularly in the fields of ophthalmology, the central nervous system, and metabolic diseases. Its lead program, NGGT-001, is currently in clinical development for Leber's Hereditary Optic Neuropathy (LHON) caused by ND4 mutations. Nuojiebei maintains integrated capabilities including a proprietary AAV technology platform and in-house GMP manufacturing facilities. The company aims to provide one-time curative treatments for patients with high unmet medical needs through its robust pipeline of genetic medicines.